We Embody a Legacy of Incredible Discoveries, Exploring the Boundaries of Innovation and Science
At Zenovel, we integrate our extensive expertise across a wide range of domains, from Good Clinical Practice to Regulatory Affairs, to present valuable insights and thought leadership. Each blog reflects our intense dedication to innovation, offering a forum to share our perspectives, groundbreaking ideas, and industry expertise. Through our blogs, we hope to uplift, inform, and support scientific, medical, and pharmaceutical innovation.
The pharmaceutical industry is growing and changing rapidly. As a result of this emergence, getting a new drug to the
In the ever-changing and competitive pharmaceutical and biotechnology industry, long-lasting success requires strategic foresight, flexibility, and a firm grasp of
Clinical trials are the backbone of pharmaceutical innovation; ensuring new treatments are safe and effective. However, managing these trials is
Moving forward into 2026, the pharmaceutical and healthcare industries are embarking on a transformation with artificial intelligence (AI) as a
In today’s era, Zenovel is enhancing Pharmacovigilance, the monitoring and evaluation of pharmaceutical products, by promoting international collaboration, utilizing advanced
Pharmacovigilance is crucial for public health, ensuring the safety and effectiveness of medicinal products throughout their lifecycle. It involves periodic
Good Manufacturing Practices Audit: At Zenovel, we prioritizes maintaining high quality standards in the pharmaceutical supply chain through GMP audits, ensuring compliance with health authority regulations, industry best practices, and current standards. As regulatory requirements evolve, there’s a growing need for enhanced vigilance and Quality Risk Management during the audit
Overview of Regulatory Oversight in Life Sciences and Pharmaceutical Companies Regulatory agencies including the FDA, EMA, PMDA, HPRA, CDSCO, and others keep a vigilant eye on the life sciences and pharmaceutical sector. These organisations are committed to safeguarding patient safety and drug-product quality. In fiscal year 2023, the FDA
Understanding Nitrosamine Impurities in Pharmaceuticals: Nitrosamines, particularly N-nitrosamines, are probable or possible human carcinogens. They can form during the synthesis of active pharmaceutical ingredients (APIs) or during the storage of finished drug products. FDA guidance emphasizes the need for risk assessment, mitigation strategies, and regulatory compliance to control nitrosamine levels.
Introduction: In-process monitoring is a critical component of ensuring the quality and reliability of BA/BE studies, especially those involving drug-drug interactions (DDIs). For DDI studies, in-process monitoring is particularly crucial due to the complex nature of interactions, the need for precise data, and the potential impact on patient safety. Key
Abstract For the past few years, regulatory bodies, industry advocacy groups, and private companies have been tackling the concept of incorporating risk into the design of clinical trials and customizing monitoring strategies based on those risks to achieve higher-quality outcomes. Regulatory guidance like ICH and FDA encourag sponsors to adopt
Introduction In the realm of inhalation studies, achieving consistent compliance and accurate results is a considerable challenge due to the complexities associated with trial conduct. Zenovel, a third-party monitoring company, boasts extensive experience in monitoring inhalation studies. This article sheds light on Zenovel’s recent involvement in the monitoring of three
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.
